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Background: Genome-wide saturation mutagenesis and subsequent phenotype-driven screening has been central
to a comprehensive understanding of complex biological processes in classical model organisms such as flies,
nematodes, and plants. The degree of “saturation” (i.e., the fraction of possible target genes identified) has been
shown to be a critical parameter in determining all relevant genes involved in a biological function, without prior
knowledge of their products. In mammalian model systems, however, the relatively large scale and labor intensity
of experiments have hampered the achievement of actual saturation mutagenesis, especially for recessive traits that
require biallelic mutations to manifest detectable phenotypes.
Results: By exploiting the recently established haploid mouse embryonic stem cells (ESCs), we present an
implementation of almost complete saturation mutagenesis in a mammalian system. The haploid ESCs were
mutagenized with the chemical mutagen N-ethyl-N-nitrosourea (ENU) and processed for the screening of
mutants defective in various steps of the glycosylphosphatidylinositol-anchor biosynthetic pathway. The resulting
114 independent mutant clones were characterized by a functional complementation assay, and were shown to be
defective in any of 20 genes among all 22 known genes essential for this well-characterized pathway. Ten mutants
were further validated by whole-exome sequencing. The predominant generation of single-nucleotide substitutions
by ENU resulted in a gene mutation rate proportional to the length of the coding sequence, which facilitated the
experimental design of saturation mutagenesis screening with the aid of computational simulation.
Conclusions: Our study enables mammalian saturation mutagenesis to become a realistic proposition. Computational
simulation, combined with a pilot mutagenesis experiment, could serve as a tool for the estimation of the number of
genes essential for biological processes such as drug target pathways when a positive selection of mutants is available.
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Genome-wide mutagenesis and subsequent phenotype-
driven screening has been pivotal to a complete under-
standing of how complex biological processes operate
in classical model organisms including flies, nematodes,
and plants [1,2]. The level of “saturation” in mutagenesis
(i.e., the fraction of possible target genes identified) has
been shown to be a critical parameter for this approach
to determine all relevant genes involved in a biological
function, without prior knowledge of the gene products
[1-3]. In mammalian model systems, much effort has
been expended to saturate, i.e., to disclose all the genes
involved in some specific biological pathways. However,
the relatively large scale and labor intensity of experi-
ments have hampered the achievement of actual sat-
uration mutagenesis, especially for recessive traits that
require biallelic mutations to manifest detectable phe-
notypes [3-6]. To overcome these drawbacks, the haploid
mouse embryonic stem cell (ESC) system, in which a
single-hit mutation can directly lead to phenotypic
changes without being compensated by the second copy
of the gene, has been recently developed [7-10], and
reviewed in [11].
Here, to address the issues of mammalian saturation
mutagenesis, we mutagenized the haploid mouse ESCs
with the chemical mutagen N-ethyl-N-nitrosourea (ENU)
and subjected them to a phenotypic screening of mutants
defective in various steps of the glycosylphosphatidylinositol-
anchor (GPI-anchor) biosynthetic pathway.
Results
The GPI-anchor biosynthetic pathway as a model target
of screening
We chose the GPI-anchor biosynthetic pathway as a model
target of phenotype-driven screening for a number of
reasons. The GPI-anchor is a glycolipid that tethers many
proteins to the plasma membrane of eukaryotic cells,
forming a diverse family of molecules including hydro-
lytic enzymes, receptors, adhesion molecules and com-
plement regulatory proteins [12,13]. The biosynthetic
pathway is mediated by sequential additions of sugars
and other components to phosphatidylinositol (Figure 1A)
[12-14]. The cell surface expression of GPI-anchored
proteins involves a total of 26 genes, which, with the ex-
ception of the X chromosome-linked phosphatidylinositol
glycan anchor biosynthesis, class A (Piga) gene, are widely
distributed throughout the autosomes (Table 1). Clos-
tridium septicum α-toxin selectively binds GPI-anchored
proteins at the cell surface and kills host cells [15]. A
defect in the GPI-anchor biosynthetic pathway does not
affect ESC proliferation per se [16], but a loss-of-function
mutation in the pathway results in an α-toxin resist-
ant phenotype, providing a platform for positive selec-
tion screening.ENU mutagenesis
Unlike some viral or transposon-based insertional muta-
gens, the DNA alkylating agent ENU can introduce a high
rate of point mutations into the genome, irrespective of
whether it hits active genes, inactive genes, or intergenic
regions [17,18]. In the present study, we used two germ-
line competent haploid mouse ESC lines, H129-2 and
HAP-1 [7,19]. After the enrichment of haploid cells by
flow sorting (Additional file 1: Figure S1A and B), H129-2
and HAP-1 ESCs were treated with 0.25 and 0.20 mg/ml
of ENU, respectively (Figure 1B). For the purpose of
further increasing the mutation rate, pretreatment with
the alkyltransferase inhibitor O6-benzylguanine (O6-BG,
10 μM) [20] was also included in the experimental design.
Most cells were killed by these treatments [20], and the re-
sidual surviving cells (0.13–0.49%; n = 4) were treated with
1 nM α-toxin to select for GPI-anchor pathway mutants.
A total of 114 resistant clones (70 from H129-2 and 44
from HAP-1) were separately isolated and subjected to the
previously described functional complementation assay
[4] involving transfection with various combinations of
plasmids encoding the 26 candidate genes (for details, see
Methods section). As a reporter, we co-transfected ESCs
with a plasmid encoding green fluorescent protein (GFP)
fused with a GPI-anchor attachment motif (GFP-GPI; see
Figure 1C). Only when the mutated gene(s) were exogen-
ously restored did the cells express GFP at their surface,
enabling mutants to be identified by their fluorescence.
Representatively, four ESC clones were also analyzed
by Sanger sequencing and their causative mutations
were detected in the corresponding GPI-pathway genes
(Additional file 2: Figure S2). Eventually, all isolated 114
clones harbored at least one mutant allele (115 mutant
alleles in total) in any of 20 known genes involved in the
GPI-anchor biosynthetic pathway (Table 1).
Among the 114 mutant ESC clones, clone B502 exhibited
fluorescence when transfected with a mixture of cDNA-
expressing vectors for all known GPI-anchor pathway
genes (26 cDNAs in total), not when transfected with a
single gene plasmid. A series of step-wise reductions in
the repertoire of cDNA-expressing vectors revealed that
both Dpm1 and Pigv cDNAs were essential to restore the
fluorescence (Figure 2A). Sanger sequencing of genomic
DNA from the B502 ESC clone identified causative point
mutations of both genes (Figure 2B–D). Thus, the appear-
ance of this double mutant in our screening suggests that
the mutagenicity of ENU is of a sufficiently high level for
saturation mutagenesis.
Haploid ESCs have an inherent tendency to become
diploid during culture [7-11]. This process, autodiploidiza-
tion, resulted in undesirable but inevitable contamination
of the diploidized ESCs (Additional file 1: Figure S1A). In
this study, 86.0% of ESCs remained haploid at the point of
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Figure 1 Experimental design. (A) Biosynthetic pathway of GPI-anchored proteins. GPI-anchor precursors are synthesized and attached to
proteins in the endoplasmic reticulum (ER). The resulting GPI-anchored proteins are expressed at the cell surface. Out of 26 genes involved in this
pathway, four (shown in red) were excluded from our screening (see text). Dol-P-Man, dolichol-phosphate-mannose. (B) Schematic screening
procedure. (C) Functional complementation assay. Upper, principle of the assay. Lower, representative culture fields of Piglm mutant ESCs
unrestored (left) and restored (right) by plasmid transfection (scale bars, 50 μm). For clarity, original images shown in Additional file 1:
Figure S1C were trimmed.
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mosomes could undergo X-inactivation or chromosomal
loss, an ENU-induced mutation on the other allele of
the X-linked gene would immediately lead to a complete
loss-of-function. This meant that, in the mixture of hap-
loid and diploid ESCs, X-linked mutants would be more
frequently obtained than autosomal recessive mutants. In
the present study, prior to mutagenesis with ENU, we in-
troduced extra copies of human PIGA cDNA into the
H129-2 haploid ESC line, but not into the HAP-1 haploid
ESC line. As a result, X-linked Piga mutants apparently
dominated in the HAP-1 ESC population (53.6% of mu-
tant clones), whereas no Piga mutants, but instead variousother autosomal mutants, appeared in the H129-2 ESC
population.
Pigg, Pign, and Pigq are known by their hypomorphic
loss-of-function phenotypes [13,22,23]. Consistently, a re-
cent ESC-based mutagenesis study using the clustered
regularly interspaced short palindromic repeats (CRISPR)-
Cas system also screened for the resistance to α-toxin and
failed to obtain Pigg, Pign, and Pigq mutants [24]. This
suggests that, apart from these three genes and Piga, the
remaining 22 genes are essential for the maintenance of
α-toxin sensitivity in our screening scheme. Because the
present mutagenesis study identified 20 of the 22 essential
genes, this corresponded to a degree of saturation of 91%.
Table 1 Genes involved in GPI-anchor biosynthesis and
their mutant alleles
No. of mutant alleles
Gene Chr CDS length (bp) H129-2 HAP-1 Total
Pigc 1 891 2 2 4
Pigm 1 1269 5 4 9
Pign 1 2793 NA* NA* NA*
Dpm1 2 780 2† 3 5
Dpm2 2 252 0 1 1
Pigt 2 1746 4 4 8
Pigu 2 1305 10 3 13
Dpm3 3 276 0 1 1
Pigk 3 1185 7 1 8
Pigo 4 3303 5 4 9
Pigv 4 1479 5† 6 11
Pigg 5 2925 NA* NA* NA*
Pgap2 7 750 1 3 4
Pigb 9 1626 7 3 10
Pigy 9 213 0 0 0
Mpdu1 11 741 0 0 0
Pigl 11 756 3 1 4
Pigs 11 1665 3 0 3
Pigw 11 1509 1 1 2
Pigh 12 564 1 0 1
Gpaa1 15 1863 6 1 7
Pigp 16 396 1 1 2
Pigx 16 756 6 3 9
Pigf 17 657 2 2 4
Pigq 17 1743 NA* NA* NA*
Piga X 1455 NA* NA* NA*
(Total) 71 44 115
*Four genes excluded from screening targets (see text).
†One H129-2 clone has two mutant alleles (see Table 2 and Figure 2).
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haploid ESCs
The degree of saturation in mutagenesis largely depends
on the mutagen. We examined 10 independent H129-2-
derived mutant ESC clones by whole-exome sequencing
(WES) and compared the results with those from ENU-
untreated parental ESC clones (Table 2 and Additional
file 3: Tables S1–S10). Over 98% of the reads were success-
fully mapped to the NCBI37/mm9 mouse reference gen-
ome with a mean coverage of 92.4, and 84.5% of the
exome regions were analyzed at >30-fold depth (Additional
file 4: Figure S3). Given that each locus has in principle
one allele, only mutations designated “homozygous” were
taken into account by our WES analytical pipeline (see
Methods).To filter out potential false-positive mutations, we adopted
the following criteria: the mutations are only positive
(i.e., “true-positive”) when >90% of reads are called
“alteration” in ENU-treated mutant ESCs and >95% of
the corresponding reads are called “reference” in ENU-
untreated control ESCs. These criteria were validated by
the Sanger sequencing of 20 “true-positive” mutations and
22 “false-positive” mutations in mutant clone F-43. As a
result, 19 of the 20 “true-positive” mutations were con-
firmed, and 0 of the 22 “false-positive” mutations were de-
tected. One mutation thought to be “true-positive” but
not detected by Sanger sequencing was near the threshold
line of our criteria. Using Fisher’s exact test, we obtained
an extremely small P value (P = 4.5 × 10−11), confirming
the appropriateness of the above criteria for filtering
WES data. Yoshida et al. previously reported a true-
positive rate of candidate mutations of only 53.9% using
WES data from patients with myelodysplastic syndrome
(MDS) [25], indicating that the haploid nature of our mu-
tant cells is advantageous for the accurate determination
of mutations compared with diploid cells such as those of
MDS patients.
Frequency and characteristics of ENU-induced mutations
We detected 10–511 mutations in the 49.3-Mb exome
region of each clone (Table 2). The average number of
mutations was 233.1, representing an overall mutation
rate of 4.72 Mb−1. Although these 10 clones were muta-
genized with ENU under the same conditions, the number
of mutations diverged between clones for as yet unknown
reasons. Nevertheless, the overall mutation rate is com-
parable to that of previous reports [18,26,27].
Most (98.5%) mutations were single-nucleotide substitu-
tions (Figure 3A) [3,18,28]. Among a total of 2,240 single-
nucleotide substitutions, the A:T base pair mutations
(45.5%) comprised similar proportions of transitions (A:T
to G:C, 20.4%) and transversions (A:T to C:G or T:A,
25.1%), whereas the G:C base pair mutations (54.6%) com-
prised a higher proportion of transitions (G:C to A:T,
46.7%) than transversions (G:C to C:G or T:A, 7.9%)
(Figure 3B and Additional file 5: Table S11). Accord-
ing to previous reports in mice including whole-genome
sequencing data, ENU-induced mutations were markedly
biased toward mutations in A:T base pairs (74.2–87%)
[17,27,29,30], which is considered to be a serious obstacle
for random mutagenesis. However, we observed a much
smaller base pair preference for A:T (45.5%) or G:C
(54.6%) at mutated positions within the exome. This may
in part be reflective of a lower A:T content in exonic DNA
regions (49.7%) compared with the entire genome (58.2%).
Alkylating agents such as ENU cause alkylation at the O6
position of guanine, leading to the G:C to A:T transition
[31], while an intrinsic repair mechanism mediated by O6-
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Figure 2 Pigv and Dpm1 are simultaneously mutated in clone B502. (A) Functional complementation assay of clone B502 ESCs. Co-transfection
of both Dpm1- and Pigv-encoding plasmids was necessary for expression of the GPI-anchored GFP reporter at the cell surface. Original magnification,
×200. Scale bars, 100 μm. (B) Sequence chromatograms of wild-type (upper) and mutant (lower) ESCs at Pigv (left) and Dpm1 (right) loci. Point
mutations at the consensus 5′ splice site sequence (GT) of Pigv intron 2 (c.78 + 1G > A) and at the nucleotide next to the consensus 5′ splice
site sequence (GT) of Dpm1 intron 7 (c.563 + 3A > T) are shown. (C) Reverse transcription polymerase chain reaction (RT-PCR) of Pigv illustrating that
intron 2 is correctly spliced in wild-type but not in mutant ESCs. The arrow indicates a transcript containing an enzymatically important region [21];
the arrowhead putatively indicates a short isoform. The left lane of the electrophoretic gels represents molecular size markers. Note that cDNA integrity
of mutant ESCs was confirmed by amplification of Actb (lower gel). (D) RT-PCR of Dpm1 illustrating that intron 7 is correctly spliced in wild-type
(white arrow) but not in mutant ESCs. The left lane represents size markers.
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haploid ESCs with the alkyltransferase inhibitor O6-BG.
As a result, G:C to A:T transitions were predomin-
antly observed, which contributes to a much smaller base
pair preference between A:T and G:C. Indeed, O6-BG was
not used in the abovementioned reports [17,27,29,30].
We used SnpEff software (v3.2) to predict the impact
of the mutations [32,33]. In brief, a “high” impact is that
assumed to be disruptive to the protein; a “moderate”
impact mutation is non-disruptive but might change the
effectiveness of the protein; a “low” impact is unlikely to
be accompanied by a change in the protein behavior; and
“modifier” impact variants usually occur in introns or
affect noncoding genes [34] (representative examples are
shown in Additional file 6: Table S12). This software clas-
sified one-half of the mutations as either “high” impact
(i.e., nonsense, splice site, frameshift, or loss-of-start-codon)
or “moderate” impact (i.e., nonsynonymous) mutations,
which narrowed down the list of candidate genes (Table 2
and Figure 3C). Thus, the analysis pipeline successfully
confirmed responsible mutations in nine out of 10 mutant
ESC clones tested: seven harbored a point mutation ofGPI-anchor pathway genes, categorized as high (three
clones) or moderate (four clones) impact; one clone was
confirmed to harbor point mutations that affected two
genes (Dpm1 and Pigv) as described above (Figure 2); and
one harbored a large deletion encompassing all exons of
the Pigk gene (Additional file 7: Figure S4). The rest (clone
F-43) harbored a mutation in the sixth exon of Pigo, which
was undetectable because of an accidental omission in the
ready-made exome capture design, so was instead con-
firmed by Sanger sequencing (Additional file 2: Figure S2).
The high success rate in mutation identification is a pre-
requisite, though is not sufficient, for the detection of
novel genes. Our data demonstrate the major contribution
of exonic mutations to the phenotypes [3] and the effect-
iveness of combining WES with a haploid-based ENU mu-
tagenesis approach.
Mutation rate for each gene depends on the coding
sequence length
The efficient and unbiased nature of ENU as a mutagen,
combined with the haploid ESC system, enabled a realistic
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Figure 3 Characteristics of ENU mutagenesis in haploid ESCs. (A) Mutation types detected by whole-exome analysis. Actual numbers of
mutations are shown in parentheses through Figure 3A–C. (B) Frequencies of nucleotide changes. The 2,240 point mutations are classified as
transitions or transversions. Fewer than 2.5% of the 2,296 single-nucleotide substitutions could not be classified by our WES analytical pipeline for
unknown reasons. We excluded these data from the analysis in Figure 3B. (C) Effects of mutations on genes predicted by SnpEff software (see also
Additional file 6: Table S12). If more than one effect was annotated on a single mutation, effects with higher impact prediction were adopted.
Table 2 Mutations identified by whole-exome sequencing




















B3-1 Pigt 220 6 5 0 0 115 39 1 54
B5-1 Dpm1 297 6 3 0 1 128 60 2 97
B7-2 Pigo 218 5 1 0 0 103 38 1 70
B102 Pigb 10 0 0 1 0 4 0 0 5
B201 Pigk† 41 1 1 0 0 14 7 0 18
B502 Dpm1, Pigv 511 13 12 1 1 241 110 5 128
B1001 Pigv 306 8 2 0 0 127 55 1 113
B1002 Pigs 330 10 2 1 0 152 63 0 102
B1007 Gpaa1 23 1 1 0 0 9 2 1 9
F-43 Pigo‡ 375 12 4 2 0 153 83 2 119
Average 233.1 10 104.6 47 71.5
*Genes whose mutations are responsible for the host cell phenotypes.
†All exons are deleted (Additional file 7: Figure S4).
‡Undetectable because of an exome design defect (Additional file 2: Figure S2).
§Also explained in Additional file 6: Table S12.
||The remainder: one codon insertion in clone B102.
¶Others: start gained; synonymous stop.
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As described above, we isolated 115 independent mutant
alleles whose causative mutations covered 20 out of 22
GPI-anchor pathway essential genes. Since most ENU-
induced mutations were single-nucleotide substitutions
(Figure 3A and B), we speculated that the mutation rate
for each gene depended on its coding sequence (CDS)
length. To confirm this, we plotted the number of mutant
alleles for each responsible gene against its CDS length
(Figure 4A), revealing a positive proportional correlation
(Pearson’s correlation r = 0.59). This result was further
validated by comparison with Monte Carlo simulation: 20
runs of 115 mutagenic hits were assigned to any of the 22
genes essential for the pathway with a probability pro-
portional to their CDS length (Figure 4B). Besides a
few outliers, the experimental mutation rate for each
gene was within the range of the simulation predic-
tions, indicating the relevance of the CDS length as a
prime determinant of gene mutation rates in this
system.
Modeling the experimental time course of the
appearance of mutant alleles
We next attempted to trace the experimental time course
of the appearance of mutant alleles by simulation. During
the experiment, the number of mutant alleles obtained
from α-toxin selection accumulated in a step-wise man-
ner: 22, 40, 71, and 115 mutant alleles, which covered 11,
15, 18, and 20 of the essential genes, respectively. The
experimentally-determined gene number at each step was






















Figure 4 ENU mutagenesis generates a CDS length-dependent rate o
length and the number of independent mutant alleles (Pearson’s correlatio
Pigl). (B) Box plots representing 20 runs of simulation for the number of m
assigned to any of the 22 genes. Bars, boxes, and whiskers indicate median
within 1.5 times the box sizes, respectively. Columns for the 22 genes are o
complementation assay are overplotted (red circles). Notably, 20 of the 22simulation. Under the simplest assumption that mutation
rates are identical for each gene, the expected gene num-
ber did not match the corresponding experimental result
at each step (Additional file 8: Figure S5). By contrast,
under the current assumption that mutation rates vary
proportionally to CDS length, the expected gene numbers
better fitted the experimental results (Figure 5A). When
the recovered allele number is accumulated up to 407, the
expected gene number will reach 22, saturating all the
known genes essential for this pathway (Figure 5B). In
other words, to achieve complete saturation, isolation of
around 400 mutant clones will be required in this experi-
mental setting.
Extended model for estimation of gene number in a
biological pathway
Finally, we extended this experimental and simulative
study of ENU mutagenesis to a general biological process.
Two critical prerequisites were a mutagenic scheme of
random single-nucleotide substitutions and independent
isolation of different mutant alleles. The former contrib-
utes to the assumption of the CDS length-dependent gene
mutation rates and the latter contributes to an accurate
enumeration of the screened mutants. Assuming that a
variable number (n) of genes is essential for a biological
pathway, the CDS length for each gene can be assigned ac-
cording to the distribution of CDS length for all mouse
genes deduced from the consensus coding sequence
(CCDS) database (Figure 6A) [35]. Using the putative CDS
length as a parameter for the simulation, we plotted the ex-
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Figure 5 Number of essential genes covered by 22, 40, 71, and 115 mutant alleles. (A) The number of essential genes covered by 22, 40,
71, and 115 mutant alleles for the GPI-anchor pathway. Histograms represent the simulative probability distribution of the covered gene numbers
using CDS length-dependent mutation rates. Expected values and experimental data are compared at the bottom of each panel. Notably, the expected
values based on the CDS length-dependent mutation rates are more consistent with the experimental data than those based on the identical mutation
rates (see Additional file 8: Figure S5). (B) The simulated number of genes covered by 407 mutant alleles.
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http://www.biomedcentral.com/1471-2164/15/1016numbers of isolated mutant alleles, where the essential
gene number, n, varies from 10 to 100 in increments of
10 (Figure 6B).
Importantly, our experimental data (i.e., the step-wise
increase of identified gene number at each step of allele
collection) demonstrated a close fit to the simulated
curve for n = 20, which provides an accurate estimate of
the number of GPI-anchor pathway genes. Using the
simulation curves, even a smaller-scale pilot experiment
that screens as few as 30–50 mutant clones can provide
an estimate of the essential gene number for a given bio-
logical process. This could serve as an advantage of ENU
mutagenesis because the CDS length-dependent muta-
tion rate is not applicable to other widely-used mutagen-















































Figure 6 Experiment-based prediction of essential gene number for a
distribution of CDS length for all mouse genes. (B) Regression curves of sim
(red circles), allows the prediction of the number of genes essential for a gDiscussion
In this study, we examined the feasibility of “saturation”
mutagenesis and screening for recessive traits in mammals
by exploiting haploid mouse ESCs where single-allele loss-
of-function mutations could immediately manifest their
phenotypes. To obtain a high mutation rate, we used the
classical alkylating chemical mutagen ENU in conjunction
with pretreatment with the alkyltransferase inhibitor O6-
BG. Mutations were screened by a plasmid-based func-
tional complementation assay and were further assessed
by WES. As a result, most exome mutations were single-
nucleotide substitutions with little base pair preference,
guaranteeing the randomness of mutagenesis in this
approach. The haploid nature of the genome provided a
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http://www.biomedcentral.com/1471-2164/15/1016(SNV) calling, compared with heterozygous SNV detec-
tion in the diploid genomes. Thus, the combination of the
haploid ESC system and WES, as two modern technolo-
gies, sheds a new light on the classical mutagenesis ap-
proach with ENU.
An important contribution of this study is that we dem-
onstrated the CDS length-dependent allele frequency of
each gene when mutated with ENU. Introducing the CDS
lengths as a parameter was a good way to simulate the
GPI-anchor pathway-mutant screening that was based on
the functional complementation assay using candidate
gene-expression plasmids. This simulation principle could
also be extrapolated to similar mutagenesis experiments
for other biological pathways. Most biological pathways
have been comprehensively investigated and at least
some of their genetic components are already known
[39]. Therefore, it is important to understand how many
other relevant genes remain to be identified and when the
screening would reach saturation. For this purpose, by
taking advantage of the simulation results in Figure 6B,
the ENU mutagenesis of haploid ESCs and a subsequent
small-scale pilot screening experiment would provide a
good estimate of the number of essential genes in a path-
way of interest.
The WES analysis could also contribute to the construc-
tion of a list of candidate genes. In a recent review [40],
Schneeberger notes that next-generation sequencing-
based methods for mutation identification will soon re-
place other methods such as genetic mapping in forward
genetic screens. The power of WES in detecting ENU-
induced mutations is also discussed, and the analysis of
pooled genomes is recommended to manage large num-
bers of samples. Indeed, considering the much higher ac-
curacy of mutation identification achieved in haploid
compared with diploid cells, deep-sequencing of pooled
DNA samples from multiple isolated clones may be a
cost-effective way to identify mutations. Typically it ap-
pears that when accumulating sequenced clones in a
positive-selection screening approach, mutations will be
enriched in a limited number of genes. Further, the more
often different mutations are found within a gene, the
more likely the gene will be a target of the screening. Not-
ably, the mutant allele frequency should be normalized by
dividing it by the CDS length, such that a gene with a
high mutant allele frequency and smaller CDS should
be given priority over that with a high allele frequency
and larger CDS.
In addition to the GPI-anchor biosynthetic pathway
we used here, our screening strategy is applicable to
many other experimental systems in which positive se-
lection of mutant clones is available. At present, several
biological pathways can be proposed as plausible targets
for forward genetic screens, including mismatch repair
genes (selected by 6-thioguanine) [7,24], genes involvedin the exit from the pluripotency circuit of ES cells (se-
lected by the Rex1–GFP reporter) [37], genes involved
in tumor necrosis factor (TNF) receptor 1 signaling (se-
lected by TNF-α) [36], and effector genes of extrinsic
apoptotic stimuli (selected by TNF-related apoptosis-
inducing ligand) [36]. Furthermore, our strategy could
be useful for investigating the pathways related to drugs
and toxins with undetermined or partially determined
mechanisms. For example, targets of the poly (ADP–ri-
bose) polymerase 1/2 inhibitor olaparib [41] and effector
genes of ricin toxicity [8] are currently under investiga-
tion. Many more compounds not yet examined could
also be considered candidates of our strategy.
The GPI-anchor biosynthetic pathway has been exten-
sively characterized [12-14], and the probability of new
gene discovery is limited. In the present screening, 20
out of the 22 known essential genes were identified.
Identification of a 23rd gene will depend on its CDS
length. If this is similar to the average CDS length of the
other 22 known genes (approx. 1,090 bp), the 23rd gene
should appear among the isolated 115 alleles with a
probability of >99% (see Methods). If its CDS length is
shorter (e.g., 213 bp, like Pigy), its discovery probability
is 64%. Therefore, the 23rd gene, if it exists, is likely to
have a shorter than average CDS length otherwise its ex-
istence is less likely. Indeed, the recent screening study
using the lentiviral CRISPR-guide RNA library identified
no additional GPI-anchor pathway genes when the same
concentration of α-toxin (1.0 nM) was used for positive
selection [24]. However, when a lower toxin concentra-
tion (0.50 nM) was used, at least four additional genes,
B4galt7, 1700016K19Rik, Cstf3, and Ext2, were identified
as modulators of α-toxin susceptibility, although they
do not directly affect the GPI-anchor biosynthetic path-
way. Taken together, these results suggest that mutagen-
esis screening of the GPI-anchor biosynthetic pathway has
almost been saturated with the 22 known essential genes.
The mutation numbers showed a marked variation and
non-normal distribution (Table 2) although the 10 clones
were mutagenized with ENU under the same conditions.
Thus far, we do not fully understand this phenomenon be-
cause, to our knowledge, there are no other reports of
haploid cells being ENU-mutagenized and their genome
deep-sequenced. It could reflect the relatively small num-
ber of mutant clones examined in this study, but further
investigation is necessary to clarify this because a skewed
distribution of ENU susceptibility may be a limitation of
our method, which is based on the randomness of ENU
mutagenesis.
Conclusions
In summary, ENU mutagenesis of the haploid mouse ESC
system allowed for a high level of saturation mutagenesis
and recessive loss-of-function screening that would have
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revealed that although ENU randomly created point mu-
tations in both genic and intergenic regions, nevertheless,
most of the phenotype-causing mutations were clustered
in exons, providing a rationale for the application of WES
technology. Importantly, ENU-induced mutations affected
each gene at a rate proportional to its CDS length. This
contributed to a reliable estimation of the number of
genes essential for a pathway under investigation, by
way of computational simulation based on a small-scale
pilot experiment. This study opens up new opportunities
for drug or toxin target screening.
Methods
Maintenance and purification of haploid ESCs
H129-2 and HAP-1 haploid ESC lines were kind gifts
from M. Leeb [7]. They were maintained in chemically
defined 2i medium [7,19] consisting of a 1:1 mixture of
Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12)
and neurobasal medium, supplemented with N-2, B-27,
non-essential amino acids, L-glutamine, 0.35% bovine serum
albumin fraction V (all from Life Technologies), 0.1 mM 2-
mercaptoethanol (Sigma-Aldrich), 1,000 U/ml of mouse
leukemia inhibitory factor (mLIF; Millipore), and 2i (1 μM
of PD0325901 and 3 μM of CHIR99021; both from Axon).
To purify the haploid cell fraction, ESCs were stained with
15 μg/ml of Hoechst 33342 (Life Technologies) at 37°C
for 30 min, then the cells on 1n peak were sorted with the
BD FACSAria II Cell-Sorting System (BD Biosciences).
Sorted cells were plated onto a 24-well plate or a T-25
flask with or without mitomycin C-treated mouse embry-
onic fibroblast (MEF) feeders, and were used for ENU
mutagenesis after several days. DNA contents of the ESCs
were evaluated using BD FACSCanto II (BD Biosciences)
after fixation in ethanol, RNase digestion, and staining with
propidium iodide (Sigma-Aldrich). Data analyses were
performed using BD FACSDiva software (BD Biosciences)
or FlowJo software (TreeStar).
Mutagenesis protocols
ENU was purchased from Sigma-Aldrich and was dis-
solved and diluted as previously described [20]. As a pre-
treatment, O6-BG (10 μM; Sigma-Aldrich), an inhibitor of
O6-alkylguanine-alkyltransferase [20], was added to the
culture medium from 1 day before to 1 day after the ENU
treatment. Random mutations were introduced into hap-
loid ESCs by treating them with ENU (0.25 mg/ml for
H129-2; 0.2 mg/ml for HAP-1) at 37°C for 2 h. After the
mutagenesis step, cells were cultured on MEF feeders in
Knockout DMEM supplemented with 20% fetal bovine
serum (both from Life Technologies), non-essential amino
acids, L-glutamine, 2-mercaptoethanol, and mLIF. One
week later, ESCs were plated on 0.1% gelatin-coated tissue
culture plates and treated with 1 nM of α-toxin at 37°Cfor 24 h. After removal of α-toxin, plates were incubated
for 6 or 7 days until individual colonies appeared. Colonies
were separately isolated and subjected to functional com-
plementation assays.
Functional complementation assay
Independently-isolated mutant ESC clones were trans-
fected with expression plasmids of candidate genes, to-
gether with the GFP-GPI reporter plasmid, using TransFast
Transfection Reagent (Promega) according to the manufac-
turer’s instructions. First, a mixture of cDNA-expressing
plasmids for all known GPI-anchor pathway genes (26
cDNAs in total) was transfected into each mutant clone.
One or 2 days later, GFP fluorescence was observed
using an IX70 inverted microscope (Olympus) or BioRevo
BZ-9000 inverted microscope (Keyence). Next, the reper-
toire of the cDNA-expressing plasmids in the mixture was
reduced in a step-wise manner to narrow down the list of
candidate genes. Finally, each mutant ESC clone was ex-
amined to determine whether a single gene plasmid could
restore the mutant phenotype.
Karyotype analysis
Karyotype analysis was performed as previously de-
scribed [6]. Images were taken using the Olympus IX70
inverted microscope with the CoolSNAP cf CCD camera
(Photometrics).
Reverse transcription polymerase chain reaction of Pigv
and Dpm1
Total RNA was isolated using the RNeasy Plus Micro
Kit (Qiagen) and converted to cDNA by the SuperScript
III First Strand Synthesis System (Life Technologies). Re-
verse transcription polymerase chain reaction (RT-PCR)
was performed using KOD FX (Toyobo) with the follow-
ing primers: Pigv, 5′-ATT TAG AAG CCG GAG GAA
GCT CAG TC-3′ (forward) and 5′-CCA GTA GGT
CAG GAA GTA GAC CAG AAC-3′ (reverse); Dpm1,
5′-CTC AAA TTC TGC TGA GAC CTG GAG CGT
CAG-3′ (forward) and 5′-CCA TCT GAA AGA CAT
AGC CTT TGG AGA CAC-3′ (reverse); Actb, 5′-CAG
GGT GTG ATG GTG GGA ATG GGT CAG AAG-3′
(forward) and 5′-TAC GTA CAT GGC TGG GGT GTT
GAA GGT CTC-3′ (reverse).
Exome-enriched library preparation and exome
sequencing
Genomic DNAs were extracted from 10 mutant ESC
clones and two ENU-untreated parental ESCs using the
DNeasy blood & tissue kit (Qiagen), and subjected to
quality assessment with gel electrophoresis and measure-
ment of DNA concentration. Exome-enriched libraries
were generated using the Agilent SureSelectXT mouse all
exon kit following the manufacturer’s recommendation. In
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ate fragments a few hundred base pairs in length, followed
by end repair, A-tailing and adaptor-ligation of both ends.
The resulting DNA fragments were then pulled down by
hybridization with the SureSelect oligo capture library,
and were PCR amplified using primers with indexes to
generate sequence libraries. These libraries were subjected
to paired-end (75–100 bp) sequencing on an Illumina
HiSeq 2000 sequencer.
Exome sequencing data processing
Raw data from Illumina sequencers were processed using
the exome analysis pipeline (Amelieff ). The pipeline per-
formed the following steps. Some sequence data were pro-
vided in BAM format and were converted to fastq format
with bam2fastx (tophat-2.0.4) [42] for use in the pipeline.
First, raw sequence data were cleaned up with QCleaner
software (Amelieff): low-quality reads (>20% of the base
calls with a Phred score <20) were discarded; reads shorter
than 32 and reads containing five or more N were also
discarded; base calls at both ends with a Phred score <20
were trimmed. Quality checks on the raw and cleaned-up
sequence data were performed by FastQC (v0.10.0) [43].
Next, the cleaned-up sequence data in fastq format were
aligned to the NCBI37/mm9 mouse reference genome,
which was fused with the decoy sequence to map the ex-
ogenous expression vectors for PIGA. BWA (v0.6.1) [44]
with default settings was used to generate mapped data
files written in SAM format. These were then converted
to BAM format with SAMtools (v0.1.18) [45], followed
by sorting. Duplicate reads were removed by Picard-tools
(v1.75) [46]. Before and after the removal of duplicate reads,
BAM files were indexed and coverage was calibrated. BED
files of the exome-enriched regions were provided by
Agilent [47].
After the elimination of duplicate reads, candidate
regions were extracted and local realignment was per-
formed with the Genome Analysis Toolkit (GATK v1.6-13)
[48]. Recalibration of the base quality scores was per-
formed with the same software. The resulting BAM files
were visualized using the Integrative Genomics Viewer
(IGV v2.1.21) [49]. SNVs and small indels were called
by GATK’s UnifiedGenotyper using default settings,
except for the modification of an optional parameter
minIndelFrac from 0.25 to 0.2. SNVs and indels were
filtered for sequencing and mapping qualities using
the GATK VariantFiltration tool: in brief, SNVs and/or
indels with low mapping quality, low sequence quality,
low coverage, strand bias and adjacent homopolymers/
SNVs were flagged. The average numbers of filtered SNVs
and indels were 60,254 and 3,888, respectively, probably
reflecting the genetic divergence between strains of
the H129 haploid cell line and the C57BL/6 J mouse
reference genome.Finally, SNVs and small indels were annotated using
SnpEff v3.2 software. The effects of mutations were
categorized into four impact groups: high, moderate,
low, and modifier [34]. Results were outputted in VCF
format.
Detection and validation of mutations
ENU-induced mutations were detected by comparing the
VCF file of each mutant ESC clone with that of the ENU-
untreated parental ESC clone using QmergeVCF software
(Amelieff). As mentioned in the Results section, the muta-
tions designated “homozygous” were filtered by the follow-
ing criteria: when >90% of reads represented “alteration”
in ENU-treated mutant ESCs and when >95% of reads
represented “reference” in ENU-untreated control ESCs.
Some mutations were validated by Sanger sequencing on
an ABI Prism 3100 genetic analyzer (Life Technologies).
Primers for amplification and sequencing are listed in
Additional file 9: Table S13.
Monte Carlo simulation of the number of GPI-anchor
pathway genes identified by screening
Monte Carlo simulation was conducted under the as-
sumption that the ENU-induced mutation rates vary
proportionally to CDS length. CDSs of the 22 GPI-
anchor pathway genes were extracted from the NCBI
RefSeq database (release 56, November 2012). Conceptu-
ally, the 22 CDSs were concatenated into continuous
blocks, of a total length of 23,982 nucleotides. Pseudo-
random numbers were generated to designate the nu-
cleotide coordinate along the concatenated blocks, and
the coordinates were assigned back to the corresponding
gene names. The operation was repeated as many times
as the total number of mutant alleles (e.g., 115 times for
115 mutant alleles).
First, after repeating this operation 115 times, we counted
the frequency of assignment to each gene. We ran this
computer experiment consecutively 20 times and pre-
sented the results as box plots (Figure 4B). Next, to simu-
late the number of genes covered by 22, 40, 71, 115, and
407 mutant alleles, the assigned gene number for each
screening step (i.e., 22, 40, 71, 115, and 407 times of oper-
ations) was counted. We generated 1 × 107 simulated data
sets for each step and created histograms by plotting
the number of covered genes on the vertical axis and
its probability on the horizontal axis. Expected values
for the number of covered genes were calculated and
compared with our experimental data. We also per-
formed the simulation by assigning the equal CDS length
to each gene under the simplest assumption that mutation
rates are identical among the 22 genes. The simulation
program was composed using Java SE development kit
7u25 (Oracle; the source code is provided in Additional
file 10).
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a biological pathway
For a given biological pathway containing a varying num-
ber (n) of genes, mutation rates for genes were assigned
according to the distribution of CDS length in all mouse
genes. The CDS lengths of all mouse genes were extracted
from the CCDS database [50]. The extracted data of CDS
lengths for 5, 15, 25, 35, 45, 55, 65, 75, 85, and 95 percen-
tiles were 378, 615, 825, 954, 1,131, 1,365, 1,617, 2,022,
2,628, and 4,131 bp, respectively, representing the diversity
of CDS lengths of all mouse genes. Conceptually, 10 bins
were defined by these 10 representative CDS lengths (bp)
and concatenated into continuous blocks. For example,
for the simulation of a pathway consisting of 40 genes
(n = 40), 4 × these 10 bins were concatenated to generate
continuous blocks with a total length of 40 genes. The al-
gorithms using pseudorandom numbers are described
above. Expected numbers of covered genes (y-axis) were
plotted against the number of mutant alleles (x-axis) for
the varying number (n) of genes essential for a biological
pathway (Figure 6B).
Assessment of the probability of identifying an unknown
gene
Providing that another unknown gene, in this case the
23rd gene, exists and has an average-sized CDS, the
probability to miss this gene in each mutant allele is the-
oretically 22/23. Then, among the already isolated 115
alleles, the probability of its existence is calculated as
follows:
1 – 22=23ð Þ115 ¼ 0:994
Supporting data
WES data from this project have been deposited [EMBL:
ERP001518, DDBJ: DRP001798]. The other data sets sup-
porting our results are included within this article and its
additional files.
Additional files
Additional file 1: Figure S1. Haploid ESCs used in our experiments.
(A) The DNA content of H129-2 ESCs was examined by propidium iodide
staining. The left gate denotes haploid cells in S phase; the right gate
diploid cells in S phase. The ratio between these two gates indicates
that 89.0% of the cells are haploid. (B) Karyotype analysis of H129-2 ESCs.
Twenty chromosomes are observed in each nucleus (dashed ovoid;
original magnification, ×400). (C) The raw images of Figure 1C (original
magnification, ×200). Note that ESCs were slightly damaged by cationic
liposome-mediated gene transfer with TransFast.
Additional file 2: Figure S2. Sanger sequencing of mutations
introduced by ENU. Nonsense mutations identified in exon 6 of Pigo
(upper left), exon 10 of Pigs (upper middle), and exon 7 of Pigu (upper
right). The frameshift mutation in exon 4 of Pigx is also shown (lower).
Additional file 3: Tables S1–S10. Detailed lists of mutations identified
by WES.Additional file 4: Figure S3. Coverage of exome sequencing in H129-2
ESC clones. Shares of the regions with indicated depths are plotted for
12 (two, control; 10, mutant) H129-2 ESC clones. Controls 1 and 2 differ in
insertion sites of the extra copies of PIGA cDNA.
Additional file 5: Table S11. Characteristics of ENU mutagenesis in
H129-2 ESCs. A total of 2,240 point mutations were classified by the
modified base pairs and the types of DNA substitution (see also Figure 3B).
Additional file 6: Table S12. Representative mutation effects
annotated by SnpEff software. A complete description is provided in [34].
Additional file 7: Figure S4. Deletion of the Pigk locus in clone B201.
(A) The coverage of mapped reads on Pigk exons is minimal (one or two)
in clone B201, which contrasts with the multiple coverage on the same
exons in control cells. Illumina sequencing data were visualized using IGV
v2.1.21. (B) The coverage of mapped reads on the neighboring Ak5
exons, 46 kb centromeric to Pigk, is recovered in clone B201 to a
comparable coverage in control cells. (C) The coverage of mapped reads
on the neighboring St6galnac5 exons, 32 kb telomeric to Pigk, is
recovered in clone B201 to a comparable coverage in control cells.
Additional file 8: Figure S5. Simulation of the covered gene numbers
based on an identical mutation rate. The numbers of essential genes
covered by 22, 40, 71, and 115 mutant alleles were simulated using an
identical mutation rate for each gene. Histograms represent the simulative
probability distribution of the covered gene numbers. Expected values and
experimental data are compared at the bottom of each panel.
Additional file 9: Table S13. Primers used for validation of WES data.
Additional file 10: Source code used in our simulation.
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